To the Editor: Dr Rowe and colleagues1 found fludrocortisone acetate to be ineffective for treating chronic fatigue syndrome (CFS). This is in sharp contrast with the results of my previous study, which found that fludrocortisone was remarkably beneficial for patients with CFS.2 Rowe et al, by administering the commercial tablets of fludrocortisone in the inappropriate form of capsules may have biased their results, because the dissolution times of tablets that are repackaged as capsules are strikingly prolonged.3 I have stated previously that "[s]lowing down the dissolution rate of a commercial drug used as a control in a clinical trial could severely bias the results of such trials."3 Administration of fludrocortisone in the improper form of capsules could also have prevented the drug from acting synchronously with the peak absorption of sodium-containing foods. This timing may be important because it could allow mineralocorticoid drugs such as fludrocortisone to maximize their sodium-retaining actions.3
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.